Development

Mezzion Pharma secures financing to advance udenafil Phase III trial in Fontan circulation

Mezzion Pharmaceuticals has announced the completion of an institutional financing round to support continued execution of the FUEL-2 trial, its global Phase III study evaluating udenafil (Jurvigo) in adolescents and young adults with Fontan circulation — a structural cardiac condition for which no therapy is currently approved specifically for this patient population.

The FUEL-2 trial (Fontan Udenafil Exercise Longitudinal Assessment Trial - 2) is a Phase III, confirmatory study being conducted across leading pediatric congenital heart centers internationally. It follows the completed Phase III FUEL trial (NCT02741115), which evaluated udenafil in a similar adolescent Fontan population. FUEL-2 is currently enrolling, and the Mezzion FUEL-2 trial financing is intended to sustain that enrollment momentum and broader operational execution.

Mezzion did not disclose the size of the financing round. The company, a US-based subsidiary of South Korean firm Mezzion Pharma Co., Ltd. (KOSDAQ: 140410), described the investors as institutional, but provided no further detail on terms or structure.

The announcement is notable in the context of rare disease pharmaceutical financing more broadly. Late-stage orphan programs with small, geographically dispersed patient populations are among the most capital-intensive in biopharma development, and securing institutional support for a confirmatory Phase III in a rare pediatric cardiac indication reflects continued investor appetite for programs with clearly defined unmet need, even in a constrained financing environment.

Fontan circulation: a disease without approved options

Fontan circulation arises from a series of staged surgical palliations performed in children born with single ventricle congenital heart disease — a group of structural cardiac defects in which only one of the two ventricles is functional. The Fontan procedure reroutes venous blood flow directly to the pulmonary arteries, bypassing the heart entirely. While this approach extends survival, it creates a chronically abnormal hemodynamic state characterized by elevated systemic venous pressure, reduced cardiac output, and impaired exercise capacity.

Patients with Fontan physiology face a progressive clinical trajectory. Exercise intolerance, arrhythmias, protein-losing enteropathy, and hepatic fibrosis are among the long-term sequelae. Median survival into adulthood has improved with surgical and medical advances, but the population remains at elevated risk of heart failure and early death compared with the general population. Despite the scale of morbidity, no pharmacologic therapy has been specifically approved for this indication by the US FDA or other major regulators.

That regulatory gap is central to Mezzion's development rationale. The company has framed udenafil as a potential first-in-class therapy specifically indicated for Fontan physiology — a designation that, if achieved, would represent the first approved pharmacologic option for this population.

The AllSci BriefSystematic R&D and deal news. Daily.

Udenafil and the PDE5 inhibitor rationale in Fontan circulation

Udenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. Its mechanism involves blocking PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which prolongs nitric oxide–dependent smooth muscle relaxation and promotes vasodilation. In the context of Fontan circulation, the rationale centers on reducing pulmonary vascular resistance and improving the passive flow of blood through the pulmonary circuit — a hemodynamic bottleneck in patients without a subpulmonary ventricle.

PDE5 inhibition is not a novel concept in congenital heart disease. Pfizer's Revatio (sildenafil) and Eli Lilly's Adcirca (tadalafil) have been studied in Fontan patients in published clinical investigations, with sildenafil appearing in Fontan-focused studies as early as 2008. However, neither sildenafil nor tadalafil has pursued a dedicated, indication-specific Phase III Fontan development program of the kind Mezzion is executing with udenafil. Cross-trial comparisons are limited by differences in study design, patient selection, and endpoints, and published clinical data for sildenafil and tadalafil in this population do not constitute a direct efficacy benchmark for udenafil.

What distinguishes the udenafil program is the specificity of its regulatory pathway. Mezzion has built a Fontan-focused clinical infrastructure across two Phase III trials, with FUEL completed and FUEL-2 now in active enrollment. That design specificity — targeting a defined pediatric and young adult population with Fontan physiology, using exercise capacity as a key endpoint — is intended to support a formal indication claim rather than off-label use.

Mezzion's development timeline for udenafil in Fontan circulation has been built over several years. Earlier work included a Phase I/II pharmacokinetic and pharmacodynamic study in adolescents (NCT02201342) and an extension study (NCT03013751), both completed, before progressing to the Phase III FUEL trial and now FUEL-2.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/


Spot something wrong? Report an issue with this article